How Fibromyalgia Causes Widespread Pain Without Visible Damage

Fibromyalgia Causes Real, Measurable Pain — The Damage Is in the Brain's Amplifier

Approximately 4 million adults in the United States are estimated to have fibromyalgia, according to the CDC — yet for much of medical history, the condition was dismissed as psychosomatic. That characterization is now considered outdated and inaccurate. Brain imaging studies using functional MRI and PET scans demonstrate objectively elevated neural responses to pressure and temperature stimuli in fibromyalgia patients. The tissues — muscles, joints, connective tissue — are structurally normal. The amplification system processing pain signals is not. Fibromyalgia is classified by the IASP (International Association for the Study of Pain) as nociplastic pain, a third mechanistic category distinct from nociceptive (tissue damage) and neuropathic (nerve damage) pain.

Central Sensitization: The Core Mechanism

The defining pathology of fibromyalgia is central sensitization — a state of heightened responsiveness of the central nervous system's pain-processing circuits. In a sensitized state, neurons in the dorsal horn of the spinal cord and in cortical pain networks have lowered activation thresholds and amplified responses. Stimuli that would be perceived as mildly uncomfortable by a healthy person trigger intense pain. Normal touch becomes allodynia. Already-painful stimuli produce a disproportionate response — hyperalgesia.

Research suggests several mechanisms drive central sensitization in fibromyalgia. Levels of substance P (a pain-facilitating neurotransmitter) in the cerebrospinal fluid of fibromyalgia patients are approximately three times higher than in healthy controls. Descending inhibitory pathways — the brain's own pain-damping system — appear to be functionally impaired, meaning the normal "volume control" on pain signals is broken. Functional MRI studies show elevated activity in the insula and anterior cingulate cortex, regions that process pain's emotional and sensory dimensions, in response to stimuli that produce minimal activation in healthy subjects.

Symptom Profile Beyond Pain

• Fatigue: Present in 90%+ of patients; often described as unrefreshing sleep regardless of duration.
• Cognitive symptoms ("fibro fog"): Difficulties with concentration, memory retrieval, and processing speed — measurable on neuropsychological testing.
• Sleep disturbance: Alpha-wave intrusion into deep sleep (Stage 3/4) disrupts restorative sleep architecture; this was one of the earliest objective findings in fibromyalgia research.
• Heightened sensory sensitivity: Noise, light, temperature, and odors are often perceived as overwhelming.
• Comorbidities: Overlapping conditions include IBS, tension headaches, temporomandibular disorder, and interstitial cystitis — all disorders now understood to involve central sensitization.

Diagnosis: ACR 2010/2016 Criteria

The American College of Rheumatology's 2010 criteria (revised in 2016) replaced the older tender point examination — 11 of 18 specific points had to be painful on 4 kg of pressure — with a questionnaire-based approach. The current criteria use two scores: the Widespread Pain Index (WPI), counting the number of body areas with pain in the past week (0–19), and the Symptom Severity Scale (SSS), rating fatigue, waking unrefreshed, and cognitive symptoms (0–12).

Fibromyalgia is diagnosed when WPI ≥7 and SSS ≥5, or WPI 4–6 and SSS ≥9, with symptoms present at a similar level for at least three months, and no other disorder that would otherwise explain the pain. Importantly, fibromyalgia can coexist with another pain condition — the diagnosis is no longer one of exclusion.

Who Gets Fibromyalgia?

The condition is significantly more prevalent in women — estimated at 7:1 female-to-male ratio in some studies, though the gap narrows under the newer diagnostic criteria that de-emphasize tender point findings. Onset typically occurs between ages 20 and 55. Risk factors include a personal or family history of mood disorders, physical trauma (particularly motor vehicle accidents), infectious illness, and other chronic pain conditions. Post-COVID-19 fibromyalgia has been reported as a component of Long COVID, consistent with the known pattern of fibromyalgia following viral illness.

Evidence-Based Treatment

• Aerobic exercise is the single treatment with the strongest evidence base across all fibromyalgia outcomes, including pain, fatigue, and quality of life. Starting low and progressing gradually is critical — symptom flares from overexertion are a common barrier.
• Duloxetine and milnacipran are FDA-approved specifically for fibromyalgia. They increase both serotonin and norepinephrine, partially restoring descending pain inhibition. Effect sizes are modest in absolute terms but clinically meaningful for many patients.
• Pregabalin reduces the excitability of central pain neurons; it was the first FDA-approved treatment for fibromyalgia (2007).
• Opioids are not recommended — research indicates they worsen central sensitization over time and are associated with poorer long-term outcomes.

This article is for informational purposes only. Consult a qualified healthcare professional for diagnosis and treatment of fibromyalgia or any chronic pain condition.